anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

191,221-191,280 of 319,975

filter-aware
10
Includes longitudinal CT scan imagery and a line chart tracking tumor diameter and volume reduction.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
Waterfall plot shows individual patient responses; ORR, PFS, and OS metrics provided.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
The slide uses a central human anatomy diagram to map specific cancer types to their respective mesothelin expression rates.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide uses a vertical process flow to link four strategic modifications to two distinct patient groups (Ovarian/Mesothelioma and NSCLC/Cholangiocarcinoma).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
TCR2 Therapeutics | Results Presentation Deck | 34 slidesTCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide uses a process diagram to illustrate the dose escalation cohorts leading to the Recommended Phase 2 Dose (RP2D).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
RP2D (Recommended Phase 2 Dose) is highlighted at DL 3.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The table categorizes adverse events into Hematologic, On Target/On Tumor, On Target/Off Tumor, and Other, with a specific highlight on the RP2D (Recommended Phase 2 Dose) column.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
Waterfall plot is a standard clinical trial visualization for tumor response.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
19
The chart uses a swimmer plot format to track longitudinal patient data including lymphodepletion status, response type, and survival.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
20
The slide presents Kaplan-Meier curves for Progression-Free Survival and Overall Survival alongside a comparative table of historical study data.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
21
Includes waterfall plot of target lesion changes and Kaplan-Meier plots for PFS and OS.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
22
Includes longitudinal CT scan imagery and a line chart tracking tumor diameter and volume reduction over time.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
23
The slide uses a scatter plot format with a shared legend for patient IDs and dose levels.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
24
Data shows patient-specific longitudinal tracking of transgene copies/µg gDNA.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
25
Patients with baseline levels of SMRP in normal range were excluded. Data cutoff: September 9, 2022.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
26
TCR2 Therapeutics | Results Presentation Deck | 34 slidesTCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
27
The chart displays individual patient responses, with multiple patients achieving significant tumor regression.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
28
The slide uses a numbered list format to categorize clinical trial improvements.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
29
Includes a futility analysis note for MPM arms and collaboration branding.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
30
The chart shows the breakdown of patient eligibility by MSLN expression levels (50%, 2+/3+ vs 50%, 1+ vs Not eligible).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
31
The chart is a swimmer plot showing patient response over time, including redosing events and disease progression.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
32
Uses multiparameter immunofluorescence to visualize tumor markers (PanCK), T cells (CD3), TAMs (CD68), and inhibitory ligands (CD155, PD-L1).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
33
The chart uses horizontal bars to represent the development stage of each program.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
34
The slide features a large stylized '2' from the company logo as a background element.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
01
Slide 1
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank 1 hit
02
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank 1 hit
03
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank 1 hit
04
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank 1 hit
05
The slide uses a central hub-and-spoke diagram to show the mast cell as the central point of failure/intervention.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
06
The data highlights the mechanism of action of KIT inhibition (inactivation and depletion) supported by Phase 1b interim results.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide presents a summary of preclinical efficacy and safety data alongside a table demonstrating high selectivity against other kinases.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide uses a staircase diagram to represent dose escalation and a crossover diagram for the food effect study.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
09
The chart displays multiple dose cohorts (200mg QD, 200mg BID, 400mg BID, 500mg QD FED) with error bars representing standard deviation.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
10
The table displays counts and percentages of subjects experiencing specific adverse events. 'MAD' stands for Multiple Ascending Dose.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
11
The chart tracks neutrophil levels across multiple cohorts (placebo, 200mg QD, 200mg Q12H, 400mg Q12H, 500mg QD FED) from Day 1 to Day 70/EOS, with a vertical line marking the end of treatment at Day 14.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
12
The slide includes a disclaimer that cross-study comparisons are unreliable due to differences in study design.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
13
Includes two line charts: one normalized to baseline and one showing absolute values.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
14
The schematic illustrates a dose escalation study with three cohorts of 10 patients each, separated by safety review committee (SRC) checkpoints.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
15
The chart shows a pharmacokinetic (PK) profile comparing two formulations of THB001.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
16
The slide uses clinical data to justify a new indication for a drug candidate by highlighting the role of mast cells in asthma pathophysiology.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
17
The slide outlines a randomized, placebo-controlled trial structure with specific allergen challenge points.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
18
The slide uses a timeline diagram to show clinical phases and key events (trial initiation, regulatory submission, data readout) from 2H'22 to 2H'24.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
19
Third Harmonic Bio | IPO Presentation Deck | 24 slidesThird Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
20
Includes a patient quote and clinical imagery to emphasize the severity of the condition.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
21
Includes medical imagery of lungs and mast cells.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
22
DART stands for developmental and reproductive toxicology.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
23
SAD = Single Ascending Dose; FE = Food Effect; PK = Pharmacokinetics; SAE = Serious Adverse Event; AE = Adverse Event; PBO = Placebo.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
24
MAD = Multiple Ascending Dose study. Data shows transient changes in reticulocytes and hemoglobin levels during treatment.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
01
Slide 1
TurnOnGreen | Investor Presentation Deck | 23 slidesTurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations 1 hit
02
TurnOnGreen | Investor Presentation Deck | 23 slidesTurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations 1 hit
03
The slide uses a timeline to show the evolution from Digital Power Corporation (1969) to the current public entity.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations 1 hit
04
The slide combines team bios with a mission statement.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · Team1 hit
05
TurnOnGreen | Investor Presentation Deck | 23 slidesTurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations 1 hit
06
The slide highlights 50+ years of expertise and lists a diverse range of clients across defense, aerospace, and commercial sectors.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations 1 hit
07
Data source: Kelley Blue Book 2022.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · Market Size1 hit
08
The chart uses a combination of bar (quarterly) and line (cumulative) data to demonstrate market acceleration.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
09
Slide highlights California as a leader in EV adoption and policy, providing quantitative market data and state-level goals.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Loop · Why Now1 hit
10
The slide uses a grid layout to map product categories against specific offerings.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
11
Uses asterisks to denote current vs future goals.TurnOnGreen | Investor Presentation Deck | 23 slides · TurnOnGreen
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit